Fresenius Kabi USA has announced FDA approval of tocilizumab (Tyenne, BLA761275) for the treatment of moderate to severe active rheumatoid arthritis, signaling the company’s continued expansion of its high-growth biologics portfolio. This strategic approval bolsters FDA competition in the rheumatology market and is expected to drive significant commercial revenue growth while leveraging the established patient demand for high-quality tocilizumab products.